Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

CJS 9th Annual “New Ideas” Investor Conference

January 7, 2009New York City

NYSE: WST

westpharma.com

All trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., unless noted otherwise.

Certain statements in the following slides and certain statements that may be made by management of the Company orally during this presentation
contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that are based on management’s plans and assumptions.Such statements give our current expectations or
forecasts of future events; they do not relate strictly to historical or current facts. We have tried, wherever possible, to identify such statements by using
words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning in connection with any
discussion of future operating or financial performance or condition.

We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties materialize, or if underlying
assumptions are inaccurate, actual results could differ materially from past results and those expressed or implied in any forward-looking statement.
You should bear this in mind as you consider forward-looking statements. We undertake no obligation to publicly update forward-looking statements,
whether as a result of new information, future events or otherwise.

Important factors that may affect future results include, but are not limited to, the following: Revenue and profitability:ales demand and our ability to
meet that demand; competition from other providers in the Company’s businesses, including customers’in-house operations, and from lower-cost
producers in emerging markets, which can impact unit volume, price and profitability; customers’ changing inventory requirements and manufacturing
plans that alter existing orders or ordering patterns for the products we supply to them; the timing, regulatory approval and commercial success of
customer products that incorporate our products, including the availability and scope of relevant public and private health insurance reimbursement for
prescription products, medical devices and components and medical procedures in which our customers’ products are employed or consumed;
average profitability, or mix, of products sold in any reporting period; maintaining or improving production efficiencies and overhead absorption; the
timeliness and effectiveness of capital investments, particularly capacity expansions, including the effects of delays and cost increases associated with
construction, availability and cost of capital goods, and necessary internal, governmental and customer approvals of planned and completed projects,
and the demand for goods to be produced in new facilities ; dependence on third-party suppliers and partners, some of which are single-source
suppliers of critical materials and products, including our Japanese partner and affiliate Daikyo Seiko, Ltd.; the availability and cost of skilled employees
required to meet increased production, managerial, research and other needs of the Company, including professional employees and persons employed
under collective bargainingagreements; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the availability
of raw materials and key bought-in components and finished products; raw-material price escalation, particularly petroleum-based raw materials, and
our ability to pass raw-material cost increases on to customers through price increases; and, claims associated with product quality, including product
liability, and the related costs of defending and obtaining insurance indemnifying the Company for the cost of such claims; the cost and progress of
development, regulatory approval and marketing of new products as a result of the Company’s research and development efforts; the defense of self-
developed or in-licensed intellectual property, including patents, trade and service marks and trade secrets; dependence of normal business operations
on information and communication systems and technologies provided, installed or operated by third parties, including costs and risks associated with
planned upgrades to existing business systems; the effects of a prolonged U.S. and global economic downturn or recession; the relative strength of the
U.S. dollar in relation to other currencies, particularly the Euro, British Pound, and Japanese Yen; changes in tax law or loss of beneficial tax incentives;

the conclusion of unresolved tax positions inconsistent with currently expected outcomes; the timely execution and realization of savings anticipated by
the restructuring plan for certain operations and functions of The Tech Group, announced in December 2007; significant losses on investments of
pension plan assets relative to expected returns on those assets, will, if sustained through year-end, result in significantly higher pension expense in
2009 and increase the Company’s pension funding obligations; and, other risks and uncertainties detailed in West’s filings with the Securities and
Exchange Commission, including our annual report on Form 10-K for the year 2007 and our periodic reports on Form 10-Q and Form 8-K.You should
evaluate any statement in light of these important.

Forward Looking Statements

Who We Are

•Founded in 1923

•Global Headquarters near
Philadelphia

•Market capitalization $1.2 billion

•World’s premier manufacturer
of components and systems
for injectable drug delivery

–Closure systems and prefillable
syringe components

–Components for disposable systems

–Devices and device sub-assemblies

–Safety and administration systems

•Stability/efficacy/shelf life •Safety; “Quality by Design” •Time to market •Component selection •Ease of use •Safety (needles and
exposure) •Convenience/Compliance •Needle safety •Ease of use •Compliance •Convenience

DRUG PACKAGING DRUG PREPARATION DRUG ADMINISTRATION

Production
Patient

West’s products and innovations address these needs

What We Do

Diverse, Stable Customer Base

Sales and Income from Continuing Operations
($ in millions)

South America

5%

North
America

49%

Europe

42%

Asia/Pacific

4%

Exubera is a registered trademark of Pfizer, Inc.

2008 Overview

•A challenging year

–Exubera, ESA packaging, diagnostic
component lost sales impact

–Commodity, currency market instability

–Global economic downturn

•Strong growth in core component sales

•Tech restructuring completed

•China plant construction underway

•Expansion programs on schedule/budget

Source: Datamonitor

Oncology &Hematology

Auto-Immune
(RA, MS, AIID)

Diabetes/Insulin

Vaccines

Market Dynamics Support Future Growth

•Increasing number of patients
with chronic illnesses

•Many of these are treated with
biologic drugs

•Biologic drugs demand ultra-
clean delivery systems

•Point of Care Shift: Hospital to
Specialty Clinic to Home

•Safe, accurate dosing needs
are pushing the market toward
integrating the container/
closure system into the delivery
system

West’s Competitive Advantage

•Global manufacturing footprint

•Unmatched experience/expertise: drug - material interface

–Global regulatory and technical support

•Protected IP: Proprietary materials and technology

•Regulatory barrier to entry:US NDA and ANDA filing must
include reference to all packaging/components in contact
with the drug

1.  West Drug Master File (DMF) 1546 is confidential

2.  West DMF includes functionality data (multi-year studies)

3.  All primary package changes require new stability/functionality
studies for new filing

•Engineering expertise in high-volume manufacturing, assembly,
and vision inspection

Drug Packaging

(How it is contained)

Primary Container Solutions

Prefillable Syringe Systems

Drug Delivery

(How it gets into the patient)

Administration Systems

Advanced Injection Systems

Development

Primary Package

Administration

Our Growth Opportunities

Corporate Growth Strategy

•Pharmaceutical Systems Segment

•Develop differentiated, value added products to
generate organic growth

•New product innovation

•Lean manufacturing

•Strategic acquisitions

•Geographic expansion

West FluroTec®
Components

Seal - Stopper - Vial

Daikyo Crystal Zenith® Vials

Estimated Market Size - $1.5 billion

CAGR - 4%

Source: Company estimate for vial systems only

West Spectra™ Seals

Crystal Zenith is a registered trademark of Daikyo Seiko, Ltd.

FluroTec and Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

Primary Packaging

Uncoated 4432/50 V35

$50

$200

4432/50 S2 FluroTec®
Westar RS

$250

4432/50 S2 FluroTec®Westar RS B2-40 Port Bag

$300

4432/50 S2 FluroTec®Westar® RS B2-40
(1000 packs)

$465

4432/50 Sterile S2 W
(RU) Ready Pack(1000 packs)

$2,900

RU Ready PackSystem
(small volume sourcing only)

$3,500

$360

Building Value in the Injectable Container Business

Corporate Growth Strategy

•Pharmaceutical Systems Segment

•Market segmentation to generate organic growth

•New product innovation

•Lean manufacturing

•Strategic acquisitions

•Geographic expansion

•China Plastics

•India Rubber site selection

Overview Plastic and Rubber plant

Plastic Plant - Construction activities

India represents a significant growth opportunity

Two regions being evaluated:

Ahmedabad

Hyderabad

Broad generic infrastructure

Rapidly growing R&D

Strong biologics focus

Corporate Growth Strategy

•Tech Group Segment

•Build market share in multi-component
systems for drug administration

•Expand proprietary product portfolio
through innovation and strategic
technology acquisitions

Vial2Bag™

Mix2Vial®

MixJect®

Total Market - $1.5 billion

CAGR - 11%

Source: Greystone Associates and Company estimate

Project Orion

Safety and Administration Systems

Critical Stability Issues for Biotechnology Drugs

•Aggregation

–Silicone, Tungsten, Glue, Mfg. Processing

•Adsorption - vials and syringes

–Impacts potency of large molecules

•Immunogenicity/Neurogenicity

•Polysorbate 20 and 80

–Detergents used for mitigating aggregation

–Highly unpredictable

•Too much creates aggregation

•Potential for peroxide creation

FluroTec® Plungers
Needle Shields, Tip Caps

Daikyo Crystal Zenith®
1mL LL Prefillable Syringe

Daikyo Crystal Zenith®
Inserted Needle Syringe

Estimated Market Size -$900 million

CAGR - 8%

Source: Company estimates

Crystal Zenith is a registered trademark of Daikyo Seiko, Ltd.

FluroTec and Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

Prefillable Syringe Systems

Higher extent of aggregation in

Glass compared to CZ

Day 0

Glass

CZ

0.00

0.05

0.10

0.15

0.20

0.25

O.D. 350

Glass

CZ

Recombinant Fusion Protein

Higher extent of aggregation in Glass compared to CZ

Daikyo Crystal Zenith®

Glass

Model antibody

Filling Trials Underway

Numerous customers are evaluating
Daikyo Crystal Zenith as both a
primary container and a prefilled
syringe in a broad range of trials

West Advanced
Injection System

Platform 2

Staked Needle Prefillable Syringe

Plunger

Primary Drug
Container

Lined
Seal

Platform 3

1mL Flanged Cartridge

Estimated MarketSize - $210 million

CAGR - 8%

Source: Greystone Associates and Company estimates

Advanced Injection Systems

Management Operating Priorities 2009

•Generate organic growth

•Improve operating margin

•Continue investing for the future

–Innovation programs

•New product launches

–Geographic expansion: China, India

–Capacity Expansion: Europe, North America

–Information systems

–Selective technology/product acquisitions

•Maximize operating cash flow - tightly manage CapEx

•Maintain a strong balance sheet

* 2008 diluted EPS from continuing operations excludes an $0.11 per share net gain on a contract settlement related to a
discontinued product line, a $0.05 per share impact of Tech restructuring charges and $0.09 per share of discrete tax
benefits.

2007 diluted EPS from continuing operations excludes $0.18 of discrete tax benefits and an $0.18 unfavorable impact for
Brazilian social security, excise and other tax compliance issues.

Nine months ended September 30,	2008	2007
Net Sales	$806.3	$764.0
Gross Margin	28.9%	29.0%
Research and Development	14.8	11.5
SG&A	122.5	112.8
Income from Continuing Ops	68.3	65.2
Diluted EPS from Continuing Ops	$1.98	$1.86
Diluted EPS from Continuing Ops (Non-GAAP) *	$1.83	$1.86

September Results
($ in millions, except per share data)

($ millions, except %)	9/30/08		12/31/07
Total Debt	$ 382.5		$ 395.1
Total Capitalization	920.5		886.0
Debt to Total Invested Capital	41.6%		44.6%
Cash	$ 102.5		$ 108.4
Net Debt to Total Invested Capital	34.2%		36.9%
Year-To-Date Capital Spending		$ 88.2	$ 129.4

Capital Management

Summary

•Fundamental business drivers remain unchanged

•Long term growth opportunities intact

•Solid balance sheet

•Seasoned, experienced management team

–Incentives closely tied to growth in shareholder value

•Year end call Thursday February 199:00AM

Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

CJS 9th Annual “New Ideas” Investor Conference

January 7, 2009New York City

NYSE: WST

westpharma.com

All trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., unless noted otherwise.